

บรรณานุกรม

รวมพร นาคพงศ์, ศิริกัลยานัน มีฤทธิ์. สถานการณ์โรคหัวใจและหลอดเลือด ปี 2549. กรมควบคุมโรค กระทรวงสาธารณสุข.

วีรวรรณ เล็กสกุลไชย. ตำราพยาธิวิทยา : การตรวจสารเคมีในเลือดและสิ่งส่งตรวจ. กรุงเทพฯ สำนักพิมพ์แห่งจุฬาลงกรณ์มหาวิทยาลัย พ.ศ. 2555.

Acevedo M, Foody JM, Pearce GL, Sprecher DL. Fibrinogen: associations with cardiovascular events in an outpatient clinic. Am Heart J 2002; 143(2): 277-82.
American Diabetes Association. Standards of medical care in diabetes–2007. Diabetes Care 2007; 30(Suppl 1): S4-S41.

Asegaonkar SB, Marathe A, Tekade ML, Cherekar L, Bavikar J, Bardapurkar J, Ajay R. High-sensitivity C-reactive protein: a novel cardiovascular risk predictor in type 2 diabetics with normal lipid profile. J Diabetes Complication 2011; 25(6): 368-70.

Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (PROCAM study). Am J Cardiol 1992; 70: 733-7.

Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in “active” coronary artery disease. Am J Cardiol 1990; 65: 168-72.

Celik T, Yuksel UC, Demirkol S, Bugan B, Iyisoy A, Kabul HK, Kilic S, Fici F, Yaman H. Relationship between increased systemic inflammation and impaired aortic elasticity in young patients with prehypertension. Blood Press Monit 2011; 16(2): 55-61.

Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.

Cooke JP, Wilson AM. Biomarkers of peripheral arterial disease. J Am Coll Cardiol 2010; 19: 2017-23.

Corrado E, Novo S. Role of inflammation and infection in vascular disease. Acta Chir Belg. 2005; 105(6): 567-79.

Corrado E, Rizzo M, Coppola G, et al. An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb. 2010; 17(1): 1-11.

- Fantuzzi G. Adipose tissue, adipokines, and inflammation. *J Allergy Clin Immunol* 2005; 115: 911-9.
- Goldhaber SZ. Risk factors for venous thromboembolism. *J Am Coll Cardiol* 2010; 56: 1-7.
- Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as risk factor for vascular disease. The European Concerted Action Project. *JAMA* 1997; 277: 1775-81.
- Grundy SM, Cleeman JL, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. *Circulation* 2004; 110: 227-39.
- Harris A, Devaraj S, Jialal I. Oxidative stress, alpha-tocopherol therapy, and atherosclerosis. *Curr Atheroscler Rep* 2012; 4(5): 373-80.
- Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. *J Cardiovasc Risk*. 1996; 3: 213.
- Horowitz LG. "Reference intervals: practical aspects", *Electronic Journal International Federation of Clinical Chemistry and Laboratory Medicine* 2008; 19(2): 1-11.
- Kougias P, Chai H, Lin PH, Yao Q, Lumsden AB, Chen C. Effects of adipocyte-derived cytokines on endothelial functions: implication of vascular disease. *J Surg Res* 2005; 126: 121-9.
- McDermott MM, Liu K, Ferrucci L, et al. Circulation blood markers and functional impairment in peripheral arterial disease. *J Am Geriatr Soc* 2008; 56(8): 1504-10.
- Miller M, Seidler A, Kwiterovich PO, Pearson TA. Long-term predictors of subsequent cardiovascular event with coronary artery disease and 'desirable' level of plasma total cholesterol. *Circulation* 1992; 86: 1165-70.
- Moreno-Aliaga MJ, Campion J, Milagro FI, Berjon A, Martinez JA. Adiposity and proinflammatory state: the chicken or the egg. *Adipocytes* 2005; 1: 1-16.
- National Cholesterol Education Program: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA*. 2001; 285(19): 2486-92.
- National Cholesterol Education Program: Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). *Circulation* 2002; 106: 3143-421.

- National Cholesterol Education Program. Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol (adult treatment panel II). *Circulation* 1994; 89: 1333-445.
- Onaka LI. Lipids, In Anderson SC, Cockayne S. (eds.). *Clinical Chemistry: Concepts and application*. Philadelphia: WB. Saunders Company, 1993.
- Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. *Circulation* 2002; 106: 388-91.
- Pearson TA, Mensah GA, Alexander, RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation* 2003; 107: 499-511.
- Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. *Circulation* 2003; 107:363-9.
- Ridker PM. Inflammation, infection, and cardiovascular risk: how good is the clinical evidence? *Circulation*. 1998; 97(17): 1671-4.
- Ridker PM, Cushman M, Stampfer MJ, et al., Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. *N Engl J Med* 1997; 336: 973-9.
- Rogowski O, Shapira I, Toker S, Melamed S, Shirom A, Zeltser D, Berliner S. Very low C-reactive protein in apparently healthy individuals: physiological status or just a reflection of an improved health profile. *Biomarkers* 2007 ;12(6) :645-56.
- Sacke FM, Willet WW. More on chewing the fat. The good fat and good cholesterol. *N Engl J Med* 1991; 325: 1740-2.
- Sadanaga T. Sadanaga M, Ogawa S, et al., Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. *J Am Coll Cardiol* 2010; 55: 2225-31.
- Soriano-Guillén L, Hernández-García B, Pita J, Domínguez-Garrido N, Del Río-Camacho G, Rovira A. High-sensitivity C-reactive protein is a good marker of cardiovascular risk in obese children and adolescents. *Eur J Endocrinol* 2008; 159(1): R1-4.
- Stec JJ, Silberschatz H, Tofler GH, et al., Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham offspring population. *Circulation* 2000; 102: 1634-8.

- Stein EA, Myers GL. Lipid, lipoprotein and apoproteins, In Burtis CA, Ashwood E. (eds.). Tietz textbook of clinical chemistry, 2nd ed. Philadelphia: WB. Saunders Company, 1994.
- Tall S AR. Plasma high density lipoprotein. Metabolism and relation to atherogenesis. *J Clin Invest* 1990; 86: 379-84.
- Tanne D, Benderly M, Goldbourt U, et al. C-reactive protein as predictor of ischemic stroke among patients with preexisting cardiovascular disease. *Stroke* 2006; 37: 1720-4.
- Thachil J, Fitzmaurice DA, Toh CH. Appropriate use of D-dimer in hospital patients. *Am J Med* 2010; 123: 17-9.
- Verhoef P, Stampfer MJ, Buring JE, et al. Homocysteine metabolism and risk of myocardial infarction: relation with vitamin B6, B12, and folate. *Am J Epidemiol* 1996; 143: 845-59.
- Vettor R, Milan G, Rossato M, Federspil G. Adipocytokines and insulin resistance. *Aliment Pharmacol Ther* 2005; 22(Suppl 2): 3-10.
- Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in diagnosis of suspected deep-vein thrombosis. *N Engl J Med* 2003; 349: 1227-35.
- Woodward M, Lowe GDO, et al. Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged man and women. The Scottish Heart Health Study. *Eur Heart J* 1998; 19(1): 55-62.
- Xu H, Barnes GT, Yang Q, et al., Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J Clin Invest* 2003; 112: 1785-8.
- Yarnell JG, Sweetnam PM, Elwood PC, et al. Hemostatic factors and ischemic heart disease. *Br Heart J* 1985; 52: 483-7.